Neurofibromatosis type II (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Neurofibromatosis type II" in English language version.

refsWebsite

Global rank English rank

34nih.gov

4^th place

19doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

2books.google.com

3^rd place

1harvard.edu

18^th place

17^th place

1lecturio.com

5,619^th place

2,948^th place

1medscape.com

719^th place

636^th place

1hopkinsmedicine.org

5,712^th place

3,986^th place

books.google.com

Christopher Gillberg (16 October 2003). Clinical Child Neuropsychiatry. Cambridge University Press. pp. 231–. ISBN 978-0-521-54335-4. Retrieved 20 December 2010.
Jean Régis; Pierre-Hugues Roche (2008). Modern Management of Acoustic Neuroma. Karger Publishers. pp. 191–. ISBN 978-3-8055-8370-1. Retrieved 20 December 2010.

doi.org

Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN; et al. (2021). "Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis". Int J Mol Sci. 22 (2): 690. doi:10.3390/ijms22020690. PMC 7828193. PMID 33445724.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A (November 2008). "The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP". Neoplasia. 10 (11): 1204–1212. doi:10.1593/neo.08642. PMC 2570596. PMID 18953429.
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (June 2009). "Neurofibromatosis type 2". Lancet. 373 (9679): 1974–1986. doi:10.1016/S0140-6736(09)60259-2. PMC 4748851. PMID 19476995.
Walter J, Kuhn SA, Brodhun M, Reichart R, Kalff R (June 2009). "Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2". Clinical Neurology and Neurosurgery. 111 (5): 454–459. doi:10.1016/j.clineuro.2008.11.018. PMID 19249154. S2CID 22696343.
Stamenkovic I, Yu Q (September 2010). "Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival". Current Protein & Peptide Science. 11 (6): 471–484. doi:10.2174/138920310791824011. PMC 2946555. PMID 20491622.
Cooper J, Giancotti FG (August 2014). "Molecular insights into NF2/Merlin tumor suppressor function". FEBS Letters. 588 (16): 2743–2752. Bibcode:2014FEBSL.588.2743C. doi:10.1016/j.febslet.2014.04.001. PMC 4111995. PMID 24726726.
Okada T, You L, Giancotti FG (May 2007). "Shedding light on Merlin's wizardry". Trends in Cell Biology. 17 (5): 222–229. doi:10.1016/j.tcb.2007.03.006. PMID 17442573.
Sherman LS, Gutmann DH (November 2001). "Merlin: hanging tumor suppression on the Rac". Trends in Cell Biology. 11 (11): 442–444. doi:10.1016/S0962-8924(01)02128-6. PMID 11684412.
Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, et al. (March 2005). "The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression". Molecular and Cellular Biology. 25 (6): 2384–2394. doi:10.1128/MCB.25.6.2384-2394.2005. PMC 1061616. PMID 15743831.
Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, et al. (August 2011). "Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression". Science Signaling. 4 (188): pt6. doi:10.1126/scisignal.2002314. PMID 21878678. S2CID 9582719.
Stepanova DS, Braun L, Chernoff J (May 2018). "A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis". Oncoscience. 5 (5–6): 126–127. doi:10.18632/oncoscience.417. PMC 6049319. PMID 30035161.
Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J (September 2017). "An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis". Cancer Research. 77 (18): 5026–5038. doi:10.1158/0008-5472.CAN-16-2834. PMC 5600854. PMID 28729415.
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (June 2009). "Neurofibromatosis type 2". Lancet. 373 (9679): 1974–1986. doi:10.1016/S0140-6736(09)60259-2. PMC 4748851. PMID 19476995.
Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, et al. (January 2017). "Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis". Neurology. 88 (1): 87–92. doi:10.1212/WNL.0000000000003418. PMC 5200853. PMID 27856782.
Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, et al. (December 2016). "Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation". Neuro-Oncology Practice. 3 (4): 281–289. doi:10.1093/nop/npv065. PMC 5909937. PMID 29692918.
Neff BA, Wiet RM, Lasak JM, Cohen NL, Pillsbury HC, Ramsden RT, Welling DB (June 2007). "Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up". The Laryngoscope. 117 (6): 1069–1072. doi:10.1097/MLG.0b013e31804b1ae7. PMID 17545869. S2CID 23086289.
Wong K, Kozin ED, Kanumuri VV, Vachicouras N, Miller J, Lacour S, et al. (2019). "Auditory Brainstem Implants: Recent Progress and Future Perspectives". Frontiers in Neuroscience. 13: 10. doi:10.3389/fnins.2019.00010. PMC 6361749. PMID 30760974.
Evans, Dgareth R. (2009). "Neurofibromatosis type 2 (NF2): A clinical and molecular review". Orphanet Journal of Rare Diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMC 2708144. PMID 19545378.
Evans DG (June 2009). "Neurofibromatosis type 2 (NF2): a clinical and molecular review". Orphanet Journal of Rare Diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMC 2708144. PMID 19545378.

harvard.edu

ui.adsabs.harvard.edu

Cooper J, Giancotti FG (August 2014). "Molecular insights into NF2/Merlin tumor suppressor function". FEBS Letters. 588 (16): 2743–2752. Bibcode:2014FEBSL.588.2743C. doi:10.1016/j.febslet.2014.04.001. PMC 4111995. PMID 24726726.

hopkinsmedicine.org

"Cochlear Implant Surgery". www.hopkinsmedicine.org. 8 August 2021. Retrieved 2021-11-29.

lecturio.com

"Ependymoma". The Lecturio Medical Concept Library. Retrieved 19 July 2021.

medscape.com

emedicine.medscape.com

"Neurofibromatosis Type 2: eMedicine Radiology". 2016-09-26. Retrieved 2010-12-20. {{cite journal}}: Cite journal requires |journal= (help)

nih.gov

pubmed.ncbi.nlm.nih.gov

Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN; et al. (2021). "Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis". Int J Mol Sci. 22 (2): 690. doi:10.3390/ijms22020690. PMC 7828193. PMID 33445724.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A (November 2008). "The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP". Neoplasia. 10 (11): 1204–1212. doi:10.1593/neo.08642. PMC 2570596. PMID 18953429.
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (June 2009). "Neurofibromatosis type 2". Lancet. 373 (9679): 1974–1986. doi:10.1016/S0140-6736(09)60259-2. PMC 4748851. PMID 19476995.
Walter J, Kuhn SA, Brodhun M, Reichart R, Kalff R (June 2009). "Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2". Clinical Neurology and Neurosurgery. 111 (5): 454–459. doi:10.1016/j.clineuro.2008.11.018. PMID 19249154. S2CID 22696343.
Stamenkovic I, Yu Q (September 2010). "Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival". Current Protein & Peptide Science. 11 (6): 471–484. doi:10.2174/138920310791824011. PMC 2946555. PMID 20491622.
Cooper J, Giancotti FG (August 2014). "Molecular insights into NF2/Merlin tumor suppressor function". FEBS Letters. 588 (16): 2743–2752. Bibcode:2014FEBSL.588.2743C. doi:10.1016/j.febslet.2014.04.001. PMC 4111995. PMID 24726726.
Okada T, You L, Giancotti FG (May 2007). "Shedding light on Merlin's wizardry". Trends in Cell Biology. 17 (5): 222–229. doi:10.1016/j.tcb.2007.03.006. PMID 17442573.
Sherman LS, Gutmann DH (November 2001). "Merlin: hanging tumor suppression on the Rac". Trends in Cell Biology. 11 (11): 442–444. doi:10.1016/S0962-8924(01)02128-6. PMID 11684412.
Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, et al. (March 2005). "The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression". Molecular and Cellular Biology. 25 (6): 2384–2394. doi:10.1128/MCB.25.6.2384-2394.2005. PMC 1061616. PMID 15743831.
Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, et al. (August 2011). "Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression". Science Signaling. 4 (188): pt6. doi:10.1126/scisignal.2002314. PMID 21878678. S2CID 9582719.
Stepanova DS, Braun L, Chernoff J (May 2018). "A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis". Oncoscience. 5 (5–6): 126–127. doi:10.18632/oncoscience.417. PMC 6049319. PMID 30035161.
Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J (September 2017). "An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis". Cancer Research. 77 (18): 5026–5038. doi:10.1158/0008-5472.CAN-16-2834. PMC 5600854. PMID 28729415.
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (June 2009). "Neurofibromatosis type 2". Lancet. 373 (9679): 1974–1986. doi:10.1016/S0140-6736(09)60259-2. PMC 4748851. PMID 19476995.
Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, et al. (January 2017). "Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis". Neurology. 88 (1): 87–92. doi:10.1212/WNL.0000000000003418. PMC 5200853. PMID 27856782.
Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, et al. (December 2016). "Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation". Neuro-Oncology Practice. 3 (4): 281–289. doi:10.1093/nop/npv065. PMC 5909937. PMID 29692918.
Neff BA, Wiet RM, Lasak JM, Cohen NL, Pillsbury HC, Ramsden RT, Welling DB (June 2007). "Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up". The Laryngoscope. 117 (6): 1069–1072. doi:10.1097/MLG.0b013e31804b1ae7. PMID 17545869. S2CID 23086289.
Wong K, Kozin ED, Kanumuri VV, Vachicouras N, Miller J, Lacour S, et al. (2019). "Auditory Brainstem Implants: Recent Progress and Future Perspectives". Frontiers in Neuroscience. 13: 10. doi:10.3389/fnins.2019.00010. PMC 6361749. PMID 30760974.
Evans, Dgareth R. (2009). "Neurofibromatosis type 2 (NF2): A clinical and molecular review". Orphanet Journal of Rare Diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMC 2708144. PMID 19545378.
Evans DG (June 2009). "Neurofibromatosis type 2 (NF2): a clinical and molecular review". Orphanet Journal of Rare Diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMC 2708144. PMID 19545378.

ncbi.nlm.nih.gov

Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN; et al. (2021). "Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis". Int J Mol Sci. 22 (2): 690. doi:10.3390/ijms22020690. PMC 7828193. PMID 33445724.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A (November 2008). "The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP". Neoplasia. 10 (11): 1204–1212. doi:10.1593/neo.08642. PMC 2570596. PMID 18953429.
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (June 2009). "Neurofibromatosis type 2". Lancet. 373 (9679): 1974–1986. doi:10.1016/S0140-6736(09)60259-2. PMC 4748851. PMID 19476995.
Stamenkovic I, Yu Q (September 2010). "Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival". Current Protein & Peptide Science. 11 (6): 471–484. doi:10.2174/138920310791824011. PMC 2946555. PMID 20491622.
Cooper J, Giancotti FG (August 2014). "Molecular insights into NF2/Merlin tumor suppressor function". FEBS Letters. 588 (16): 2743–2752. Bibcode:2014FEBSL.588.2743C. doi:10.1016/j.febslet.2014.04.001. PMC 4111995. PMID 24726726.
Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, et al. (March 2005). "The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression". Molecular and Cellular Biology. 25 (6): 2384–2394. doi:10.1128/MCB.25.6.2384-2394.2005. PMC 1061616. PMID 15743831.
Stepanova DS, Braun L, Chernoff J (May 2018). "A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis". Oncoscience. 5 (5–6): 126–127. doi:10.18632/oncoscience.417. PMC 6049319. PMID 30035161.
Stepanova DS, Semenova G, Kuo YM, Andrews AJ, Ammoun S, Hanemann CO, Chernoff J (September 2017). "An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis". Cancer Research. 77 (18): 5026–5038. doi:10.1158/0008-5472.CAN-16-2834. PMC 5600854. PMID 28729415.
Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR (June 2009). "Neurofibromatosis type 2". Lancet. 373 (9679): 1974–1986. doi:10.1016/S0140-6736(09)60259-2. PMC 4748851. PMID 19476995.
Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, et al. (January 2017). "Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis". Neurology. 88 (1): 87–92. doi:10.1212/WNL.0000000000003418. PMC 5200853. PMID 27856782.
Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, et al. (December 2016). "Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation". Neuro-Oncology Practice. 3 (4): 281–289. doi:10.1093/nop/npv065. PMC 5909937. PMID 29692918.
Wong K, Kozin ED, Kanumuri VV, Vachicouras N, Miller J, Lacour S, et al. (2019). "Auditory Brainstem Implants: Recent Progress and Future Perspectives". Frontiers in Neuroscience. 13: 10. doi:10.3389/fnins.2019.00010. PMC 6361749. PMID 30760974.
Evans, Dgareth R. (2009). "Neurofibromatosis type 2 (NF2): A clinical and molecular review". Orphanet Journal of Rare Diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMC 2708144. PMID 19545378.
Evans DG (June 2009). "Neurofibromatosis type 2 (NF2): a clinical and molecular review". Orphanet Journal of Rare Diseases. 4: 16. doi:10.1186/1750-1172-4-16. PMC 2708144. PMID 19545378.

ninds.nih.gov

"Neurofibromatosis Information Page". National Institute of Neurological Disorders and Stroke. Retrieved June 16, 2019.

semanticscholar.org

api.semanticscholar.org

Walter J, Kuhn SA, Brodhun M, Reichart R, Kalff R (June 2009). "Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2". Clinical Neurology and Neurosurgery. 111 (5): 454–459. doi:10.1016/j.clineuro.2008.11.018. PMID 19249154. S2CID 22696343.
Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, et al. (August 2011). "Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression". Science Signaling. 4 (188): pt6. doi:10.1126/scisignal.2002314. PMID 21878678. S2CID 9582719.
Neff BA, Wiet RM, Lasak JM, Cohen NL, Pillsbury HC, Ramsden RT, Welling DB (June 2007). "Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up". The Laryngoscope. 117 (6): 1069–1072. doi:10.1097/MLG.0b013e31804b1ae7. PMID 17545869. S2CID 23086289.